Limited spread of penicillin-nonsusceptible pneumococci, Skane County, Sweden.
Increasing frequencies of penicillin-nonsusceptible pneumococci (PSNP) (MIC of penicillin [greater than or equal to] 0.12 mg/L) became a worldwide problem in the 1980s (1,2). The rapid increase in frequency is likely caused by intercontinental spread of a few PNSP clones for which MICs of penicillin are high (3 6). For a long period, very low PNSP frequencies were noted in Sweden (2%-3%) (7). However, in the early 1990s, the incidence of PNSP increased from 8% to 10% in Skane, the southernmost county, while the test of the country reported unchanged low frequencies (8-10). When considered from the perspective of international experience, in which the rate of PNSP rapidly increased when this level of resistance was reached (11), the increasing frequencies of PNSP in Skane County led to the formation of an expert committee, appointed by the National Board of Health and Welfare. This committee proposed a national strategy in 1995, based on reducing unnecessary use of antimicrobial agents and applying infection control measures to limit the more immediate spread of PNSP for which MICs of penicillin were high ([greater than or equal to] 0.5 mg/L, PRP), especially in preschool children ages 1 to 6 years. In 1996, infection and carriage with PRP became notifiable by the Swedish Communicable Disease Act. The reasons to choose MIC [greater than or equal to] 0.5 mg/L as a limit for intervention were that epidemiologic data on pneumococci suggested that an increased prevalence of strains for which the MIC of penicillin was [greater than or equal to] 1.0 mg/L most often was caused by spread of a few already resistant clones, so that those strains could lead to treatment failures, and that those strains were relatively rare in Sweden in 1994 (12). Since the Etest tan be hard to interpret, MIC [greater than or equal to] 0.5 mg/L was chosen so strains for which the MIC of penicillin was 1.0 mg/L would not be missed. The decision of whether to follow the recommendations of the expert committee is made by each county department for communicable disease control. The recommendations were strictly applied in Skane County (South Swedish Pneumococcal Intervention Project, SSPIP), while some Swedish counties either did not follow the recommendations at all or only applied parts of the recommendations. For a long period, Skane County had the highest use of antimicrobial agents in Sweden, especially of macrolides and broad-spectrum antibiotics (13), and in the SSPIP traditional communicable disease control measures are combined with actions aimed at reducing the use of antimicrobial drugs. Experiences from the first 2 years of the SSPIP from parts of Skane County have previously been reported (14-17). For example, data on individual risk factors for carriage of PNSP have been evaluated. We discuss the overall results of the SSPIP and evaluate the effects of the recommendations in Skane County during the first 6 years they were implemented.
Materials and Methods
On January 1, 2000, the population of Skane County was 1,129,424 inhabitants; 93,051 were [less than or equal to] 6 years of age. The county is divided into 33 municipalities. The largest municipality, Malmo, had 259,579 inhabitants and of those, 20,325 were [less than or equal to] 6 years of age. The smallest municipality had 6,745 inhabitants; 581 were [less than or equal to] 6 years. During the study period, [approximately equal to] 76% of the children 1 to 6 years of age were enrolled in day care.
The principles of the SSPIP have been described earlier (16). In brief, all persons in Skane County with a culture that yields penicillin-nonsusceptible pneumococci with an MIC [greater than or equal to] 0.5mg/L for penicillin (PRP), regardless of resistance to any other antibiotics, have since 1995 been reported to the Regional Center of Communicable Disease Control (CCDC). Whenever a person with a clinical infection caused by PRP (index case-patient) is identified, nasopharyngcal cultures are obtained from family members and other close contacts to identify asyrnptomatic PRP carriers (contact case-patients). All carriers are followed weekly with nasopharyngeal cultures at the local primary health care center until two consecutive cultures that yield no growth of PRP (PRP-negative) have been obtained. If the index case is in a child attending any form of group day care, nasopharyngeal cultures are obtained from the other children and staff members at that day care group. Preschool children are restricted from attending day care until they are PRP-negative. In selected cases, eradication therapy with antimicrobial drugs is considered after 2 to 3 months of carriage, or earlier when strong social reasons exist (18).
The pneumococcal strains considered in this study were recovered from cultures analyzed at the Departments of Clinical Microbiology in Lund, Malmo, Helsingborg, and Kristianstad from July 1, 1995, through June 30, 2001. These four laboratories served the entire population of Skane County during the study period. The specimen were cultured on blood agar plates, and the isolates were identified as Streptococcus pneumoniae on the basis of colony morphology and susceptibility to optochin (19). The strains were screened for penicillin-resistance by using the disk-diffusion method, according to the Swedish Reference Group for Antibiotics (SRGA). The strains were inoculated onto Iso Sensitest agar (Oxoid Ltd, Basingstoke, UK), supplemented according to the recommendations, and the antibiotic disks (Oxoid Ltd) were applied. Inhibition zones were read to the nearest millimeter and interpreted according to SRGA guidelines (20). For pneumococci with an oxacillin 1 [micro]g inhibition zone <20 mm, the MIC of penicillin was determined by the Etest (AB Biodisk, Solna, Sweden) (21). The susceptibility to other antimicrobial agents (erythromycin, tetracycline, trimethoprim-sulfamethoxazole, and clindamycin) was determined by using the disk diffusion method (10). Strains from each patient were registered only once per season, even if multiple cultures were positive for pneumococci. Whether the strains were recovered at a visit to the doctor or by contact tracing or screening was noted. Serotyping to the group level was performed by the quellung reaction, by using antisera from the Statens Seruminstitut, Copenhagen, Denmark (19).
Antimicrobial Drug Use
Data were collected regarding antimicrobial drug prescriptions for outpatient care, served at Swedish pharmacies from July 1, 1995, through June 30, 2001, that were issued for children ages [less than or equal to] 6 years who lived in Skane County; these data were obtained from the Corporation of Swedish Pharmacies, which owns all Swedish pharmacies and collects and compiles information on all drugs sold in the country (13). The municipality of the patient was registered. The prescribed antimicrobial agents were given as prescriptions per 1,000 inhabitants ages [less than or equal to] 6 years per season, and all prescriptions of phenoxymethylpenicillin (PcV), ampicillin/amoxicillin (including amoxicillin+ clavulanic acid), cephalosporins, trimethoprim-sulfamethoxazole, macrolides, clindamycin, and other antimicrobial drugs (grouped together) were registered.
During the project, the frequency of PNSP carriers from clinical nasopharyngeal cultures has been evaluated. Cultures taken at contact tracing were excluded. From July 1, 1995, until June 30, 2001, the average frequency of PNSP carriers has been stable, approximately 7.4% (2,750 PNSP/34,745 pneumococci) (Figure 1). The highest frequencies (8.1%) were seen in 1997 to 1998. During the 6 years of the recommendations, the levels of PNSP have been unevenly distributed over the county; higher and stable levels were round in the city of Malmo in the southwestern part of the county, (11.3%, 976 PNSP/8,651 pneumococci) and lower, but stable, levels were found in the northeastern part of the county (4.3%, 395 PNSP/9,109 pneumococci). The frequency of PNSP among invasive pneumococcal strains (blood and cerebrospinal fluid cultures) in Skane County has been low, [greater than or equal to] 2.5 % (22 PNSP/858 pneumococci). As with the PNSP in nasopharyngeal cultures, the highest frequencies of invasive PNSP were seen in 1997 to 1998.
[FIGURE 1 OMITTED]
The average frequency of index case-patients with PRP (that is, the number of clinical case-patients with a culture with growth of PRP, divided by the number of pneumococci found in nasopharyngeal cultures) has been rather stable since the start of the project, [approximately equal to] 2.6% (905 PRP/34,745 pneumococci) (Figure 1). In the southwestern part of the county, in the cities of Malmo and Lund and surrounding municipalities, where most cases were found, PRP have been constantly present. However, in several of the smaller municipalities, PRP were prevalent during one or two seasons but then disappeared. In two municipalities, both situated in the northeast, no cases of PRP infection have been round. The proportion of cases with PRP with high MICs ([greater than or equal to] 2 mg/L) of penicillin has not increased during the 6 years (Table). Carriers of PRP with MIC[greater than or equal to] 4.0 mg/L have all been adopted children or immigrants from Eastern Europe or from countries outside Europe.
During the 6-year period, 2,269 PRP carriers (1,865 persons) have been registered at the CCDC in Skane County. Of the 2,269 PRP carriers, 40% were index case-patients, and 60% were contacts. Few contact cases have been found in persons at the extremes of ages ([less than or equal to] 1 year and >65 years). The number of contact cases per index patients in children [less than or equal to] 6 years of age has, on an average, been 1.6 (1.1 to 2.2 per season) and has not increased. The index patients have most often been found through positive nasopharyngeal cultures, and only a minority (n = 13, 1.4%) have been found through positive blood or cerebrospinal fluid cultures. More men carried PRP overall, but in the group ages 18 to 64 years, PRP carriage was more common among women. A clear seasonal variation in the incidence of PRP was found; considerably more cases occurred during the winter months (October-March) than during summer. The median duration of PRP carriage was 21 days (range 2-368 days); 1,704 (75%) of the PRP patients were children 1 tri 6 years of age. Seventy-one percent of these children attended day care centers; 6% attended family day care, and 23% were cared for at home. The other contacts have primarily been siblings, parents, or grandparents of young children.
Two hundred and twenty-seven children with a clinical culture showing growth of PRP, led to screening of children and staff at 227 of the county's 1,250 day care centers. The number of contact cases per index case-patient among all children attending these day care centers has, on an average, been 3.46 (2.6-4.2 per season) and has not increased, and the number of contact cases in each day care center has varied from 0 to 25 (median 2). In 24% of the day care center interventions, no contact cases were found. In 45 of the 227 day care centers, more than one PRP serotype was discovered, and 65 day care centers have been investigated twice or more (median 2, range 2 6). Twenty-two of these day care centers had two outbreaks with the same serotype within 6 months. Most of the day care interventions took place in the southwestern part of the county. Only 20 of all screened staff at day care centers were PRP-positive.
Serotyping to the group level was performed for 2,131 (94%) of the 2,269 PRP strains. Twenty-five serotypes of PRP were found. Six serotypes comprised 93% of the strains (serotypes 9, 19, 6, 23, 15, 14). The most prevalent strain, serotype 9, represented an average of 48% of the PRP strains (37% 66% per season). This strain has spread over the county from municipality to municipality in a clear pattern, whereas the other common serotypes have spread more randomly.
The use of antimicrobial agents in outpatient care in Skane County decreased from the first to the last season in all age groups, but especially in children aged [less than or equal to] 6 years (Figure 2). The main reduction among children ages [less than or equal to] 6 years was caused by a decrease in number of prescriptions for phenoxymethylpenicillin, and the use of macrolides was reduced by 50%. Even though the decreased use of antimicrobial drugs was seen in all municipalities, the municipalities with the highest utilization in 1995-1996 still had the highest use in 2000-2001. Those municipalities were all located in the southwestern part of the county.
[FIGURE 2 OMITTED]
In Skane County, where PNSP (pneumococci with an MIC for penicillin [greater than or equal to] 0,12 mg/L) have been prevalent for >10 years, the frequency of PNSP in clinical nasopharyngeal cultures (cultures taken at contact tracing excluded) remained of the same level in 2000 to 2001 as in 1995 to 1996, on average, 7.4%. In the city of Malmo, where the spread of PNSP appears to have started, the average level of PNSP bas been higher (11.3%) during the project period. In contrast, the average level of PNSP remained low (4.3%) during the study period in the northern and eastern parts of the county. Furthermore, the number of PRP contact cases per index case among children attending day care centers did not increase during the 6-year period. These data indicate that the rapid spread of PNSP that started in the southwestern part of the county in the beginning of the 1990s (8,9) bas been limited. These results are unique in comparison with experience in other countries, where PNSP rates have rapidly increased after reaching an 8% PNSP level (11). The proportion of contacts with PRP with high MICs of the PNSP in Skane County has not increased during the 6-year period, contrary to results from most other countries, which report increasing frequencies of PNSP with high MICs (22,23).
One of the project's aims was to decrease unnecessary use of antimicrobial agents, especially of macrolides and trimethoprim-sulfamethoxazole, which in studies have been shown to promote spread of PNSP (17,24-27). During the study period, the use of antimicrobial drugs decreased in all municipalities in the county, and the decrease was most prominent in children ages [less than or equal to] 6 years. In this age group, the use of macrolides was cut in half. The use of long-acting macrolides has been extremely low and has comprised <3% of the total use of macrolides among children. Even though the use of antimicrobial agents decreased in all municipalities of Skane County, those with high usage in 1995 to 1996 also had high usage in 2000 to 2001, and those with low usage in 1995 to 1996 had an even lower usage in 2000 to 2001. Mirroring the use of antimicrobial agents, the occurrence of PNSP has been unevenly distributed in the county, with constant high rates in the southwestern part and low levels in the northern and eastern parts. In cities in the northeastern parts and in the smaller municipalities, with lower antimicrobial agent use, single outbreaks have occurred without any more cases being reported later. A possible explanation for this might be that municipalities in which antibiotics are frequently used have a higher risk of spreading PNSP in the community, as indicated by previously published data from the project as well as by other studies (17,24,28,29).
Many PRP serotypes were found in the county during the six seasons. However, one serotype, serotype 9, has dominated during all six seasons and has spread in a clear pattern from municipality to municipality throughout the county (15), while other strains have spread more randomly in time and geographically. Why this strain has been persistently present for such a long time is unclear.
We chose to present the figures for the frequency of PNSP in clinical cultures over time, excluding cultures taken at contact tracing, since the contacts were not found at random, but rather represented a selected population around an index patient. The exclusion of cultures taken at contact tracing ought to give more fair figures when comparing data from the study period with the "resistance situation" before the project started or with data from other studies. The possibility of excluding all cultures taken at contact tracing retrospectively was not 100% guaranteed, but cultures taken at day care center screenings were easily found and excluded. The test of the cultures obtained because of contact tracing constituted only a small proportion of cultures, and thus they should not be a source of error.
Although the indication for nasopharyngeal sampling was not changed during the study period, the number of obtained samples has decreased since the start of the project. However, the number of nasopharyngeal cultures increased in 1995 to 1996 compared to 1993 to 1994. One possible explanation for this might be that the health authorities encouraged doctors to take nasopharyngeal samples more frequently during the first years of the project.
Exactly comparable data on PNSP frequencies from other Swedish counties or comparable survey data (nasopharyngeal cultures) from other countries are hard to find. However, since 1996, Swedish law has mandated the reporting of all PRP strains to the Swedish Institute for Infectious Disease Control. Data from this national register contains information on reported PRP from all over Sweden from 1997 to 2002. Of all reported PRP, the PRP from Skane County comprised 40% in 1997, but only 10% in 2002 (Figure 3). Furthermore, the recommendations are strictly applied in Skane County, white some Swedish counties either do not follow the recommendations at all or only apply parts of the recommendations. In some counties, where the recommendations were not applied or not as strictly applied as in Skane County, the frequencies of PRP have increased from 2000 to 2002 (30,31). Moreover, according to data from the annual Resistance Surveillance and Quality Control Programme, the frequency of PNSP in clinical nasopharyngeal cultures in Sweden has increased from 3.8% in 1994 to 6.2% in 2002 (30,32). In addition, the frequency of PNSP among invasive pneumococcal strains in Sweden has, on average, increased from 1.4% in 1999 to 2.4% in 2002 (30,33), but the frequency of invasive PNSP during the same period in Skane County has been approximately 2.5% and stable. The numbers of invasive PNSP isolates in Skane County are very low, and therefore drawing any reliable conclusions from these data is difficult. However, the frequency of PNSP has not increased, as it has in most other countries, and the trends of invasive PNSP seem to follow the trends for PNSP from nasopharyngeal cultures. Compared to the other Nordic countries, who still report low frequencies of invasive PNSP, Sweden has had the lowest frequencies of invasive PNSP between 1999 and 2002 (33).
[FIGURE 3 OMITTED]
Although the frequencies of PNSP in Skane County were not reduced, the spread of PNSP seems to have been limited. Whether this is a result of the actions of the SSPIP among children or of the decreased use of antibiotics in the county, or both, is impossible to tell since these actions were started simultaneously. In other countries, actions against unnecessary use of antimicrobial drugs bas been the only measure of combating the spread of PNSP, in most cases with little success, probably in part because the actions have been initiated in a much later phase, when frequencies of PNSP were higher (34-37). Still, further efforts are necessary to reduce the prescribing of antimicrobial agents in the southwestern areas, since the use of antimicrobial agents is still high there and poses the greatest risk factor for PNSP carriage.
Table. Distribution of MICs of penicillin for all registered PRP cases in Skane County per season (a) [greater than or equal to] Season 0.5 mg/L, n (%) 1.0 mg/L, n (%) 2.0 mg/L, n (%) 1995-1996 217 (33) 290 (44) 151 (23) 1996-1997 132 (36) 140 (37) 102 (27) 1997-1998 189 (42) 214 (47) 52 (11) 1998-1999 124 (46) 140 (52) 4 (2) 1999-2000 183 (59) 111 (35) 18 (6) 2000-2001 124 (62) 75 (38) 0 (a) PRP, pneumococci with MIC [greater than or equal to] 0.5 mg/L.
We thank Einar Larsson, Tony Eden, Mats Walder, and Bjorn Nilsson for their kind help with gathering laboratory data on nasopharyngeal cultures during the study period.
This work was supported by grants from the Knut and Alice Wallenbergs Foundation and the Swedish Strategic Programme for the Rational Use of Antimicrobial Agents and Surveillance of Resistance.
(1.) Appelbaum PC. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis. 1992;15:77-83.
(2.) Baquero F, Martinez-Beltran J, Loza E. A review of antibiotic resistance patterns of Streptococcus pneumoniae iii Europe. J Antimicrob Chemother 1991;28 (Suppl C):31-8.
(3.) Soares S, Kristinsson KG, Musser JM, Tomasz A. Evidence for the introduction of a multiresistant clone of serotype 6B Streptococcus pneumoniae from Spain to Iceland in the late 1980s. J Infect Dis. 1993;168:158-63.
(4.) Munoz R, Coffey TJ, Daniels M, Dowson CG, Laible, G, Casal J, et al. Intercontinental spread of a multiresistant clone of serotype 23F Streptococcus pneumoniae. J Infect Dis. 1991 ; 164:302-6.
(5.) Klugman KP, Coffey TJ, Smith A, Wasas A, Meyers M, Spratt BG. Cluster of an erythromycin-resistant variant of the Spanish multiply resistant 23F clone of Streptococcus pneumoniae in South Africa. Eur J Clin Microbiol Infect Dis. 1994;13:171-4.
(6.) Hermans PW, Sluijter M, Dejsirilert S, Lemmens N, Elzenaar K, van Veen A, et al. Molecular epidemiology of drug resistant pneumococci: toward an international approach. Microb Drug Resist. 1997;3:243-51.
(7.) Olsson-Liljequist B, Burman LG, Kallings I. Antibiotic susceptibility of upper respiratory tract pathogens in Sweden: a seven year follow-up study including loracarbef. Swedish Respiratory Tract Study Group. Stand J Infect Dis. 1992;24:485-93.
(8.) Ekdahl K, Kamme C. Increasing resistance to penicillin in Streptococcus pneumoniae in southern Sweden. Stand J Infect Dis. 1994;26:301-5.
(9.) Forsgren A, Walder M. Antimicrobial susceptibility of bacterial isolates in south Sweden including a 13-year follow-up study of some respiratory tract pathogens. APMIS. 1994;102:227-35.
(10.) Olsson-Liljequist B, Larsson P, Walder M, Miorner H. Antimicrobial susceptibility testing in Sweden. III. Methodology for susceptibility testing. Scand J Infect Dis. 1997;105 (Suppl):13-23.
(11.) Baquero F. Pneumococcal resistance to beta-lactam antibiotics: a global geographic overview. Microb Drug Resist. 1995;1:115-20.
(12.) Tull P, Burman LG, Eriksson M, Kalin M, Persson K. Pncumococci with reduced susceptibility to penicillin: background and analysis of the situation in Sweden 1995 [in Swedish]. Expert Report. Stockholm: Socialstyrelsens kundtjanst; 1997:1-32.
(13.) Swedish Drug Statistics 1995 2001. Stockholm: Apoteket AB; 1995-2001.
(14.) Ekdahl K, Ahlinder I, Hansson HB, Melander E, Molstad S, Soderstrom M, et al. Duration of nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae: experiences from the South Swedish Pneumococcal Intervention Project. Clin Infect Dis. 1997;25:1113-7.
(15.) Melander E, Ekdahl K, Hansson HB, Kamme C, Laureu M, Nilsson P, et al. Introduction and clonal spread of penicillin and trimethoprim/sulfamethoxazole-resistant Streptococcus pneumoniae, serotype 9V, in southern Sweden. Microb Drug Resist. 1998;4:71-8.
(16.) Ekdahl K, Hansson HB, Molstad S, Soderstrom M, Walder M, Persson K. Limiting the spread of penicillin-resistant Streptococcus pneumoniae: experiences from the South Swedish Pneumococcal Intervention Project. Microb Drug Resist. 1998;4:99-105.
(17.) Melander E, Molstad S, Persson K, Hansson HB, Soderstrom M, Ekdahl K. Previous antibiotic consumption and other risk factors for carriage of penicillin-resistant Streptococcus pneumoniae in children. Eur J Clin Microbiol Infect Dis. 1998;17:834-8.
(18.) Ekdahl K, Holmdahl T, Vejvoda M, Persson K. Eradication of penicillin-resistant Streptococcus pneumoniae in nasopharynx with antibiotic combinations including rifampicin: experiences from the South Swedish Pneumococcal Intervention Project. Stand J Infect Dis. 1997;29:373-5.
(19.) Lund E, Henrichsen J. Laboratory diagnosis, serology and epidemiology of Streptococcus pneumoniae. Methods Microbiol. 1978;12:241-62.
(20.) Swedish Reference Group for Antibiotics [cited 2004 Apr 22]. Available from: htlp://www.srga.org
(21.) Skulnick M, Small GW, Lo P, Patel MD, Porter CR, Low DE, et al. Evaluation of accuracy and reproducibility of E-test for susceptibility testing of Streptococcus pneumoniae to penicillin, cefotaxime, and ceftriaxone. J Clin Microbiol. 1995;33:2334-7.
(22.) Felmingham D, Washington J, the Alexander Project Group. Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens-findings of the Alexander Project 1992-1996. J Chemother. 1999; 11:5-21.
(23.) Felmingham D, Grunebergand RN, the Alexander Project Group. The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens before community acquired lower respiratory tract infections. J Antimicrob Chemother. 2000;45:191-203.
(24.) Melander E, Ekdahl K, Jonsson G, Molstad S. Frequency of penicillin-resistant pneumococci in children is correlated to community utilization of antibiotics. Pediatr Infect Dis J. 2000;19:1172-7.
(25.) Varon E, Levy C, De La Roque E, Boucherat M, Deforche D, Podglajen I, et al. Impact of antimicrobial therapy on nasopharyngeal carriage of Streptococcus pneumoniae, Haemophilus influenzae, and Branhamella catarrhalis in children with respiratory tract infections. Clin Infect Dis. 2000;31:477-81.
(26.) Ruhe JJ, Hasbun R. Streptococcus pneumoniae bacteremia: duration of previous antibiotic use and association with penicillin resistance. Clin Infect Dis. 2003;36:1132-8.
(27.) Arason VA, Kristinsson KG, Sigurdsson JA, Stefansdottir G, Molstad S, Gudmundsson S. Do antimicrobials increase the carriage rate of penicillin resistant pneumococci in children? Cross sectional prevalence study. BMJ. 1996;313:387-91.
(28.) Diekema DJ, Brueggemann AB, Doern GV. Antimicrobial use and changes in resistance in Streptococcus pneumoniae. Emerg Infect Dis. 2000;6:552-6.
(29.) Bronzwaer S, Cars O, Bucholz U, Molstad S, Goettsch W, Veldhuijsen IK, et al. A European study on the relationship between antimicrobial use and antimicrobial resistance in Europe. Emerg Infect Dis. 2002;8:278-82.
(30.) Swedish Research 2002. A report on Swedish antibiotic utilisation and resistance in human medicine [cited 2004 Apr 22]. Available from: www.strama.se
(31.) Swedish Institute for Infectious Disease Control. Surveillance statistics on notifiable diseases [cited 2004 Apr]. Available from: http://gis.smittskyddsinstitutet.se/ naapapp/build/21-13 5000/Disease_eng.html
(32.) Antibiotic resistance surveillance in Sweden-ResNet [cited 2004 Apr 22]. Available from: http://www.srga.org/ResNet_sok.htm
(33.) European Antibiotic resistance Surveillance System (EARSS) [cited 2004 Apr 22]. Available from: http://www.earss.riwaa.nl
(34.) Zhanel GG, Palatnick L, Nichol KA, Belyou T, Low DE, Hoban DJ, et al. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Candian respiratory organism susceptibility study, 1997-2002. Antimicrob Agents Chemother. 2003;47:1867-74.
(35.) Arason VA, Gunnlaugsson A, Sigurdsson JA, Erlendsdottir H, Gudmundsson S, Kristinsson K. Clonal spread of resistant pneumococci despite diminished antimicrobial use. Microb Drug Resist. 2002;8:187-92.
(36.) Hennessy TW, Petersen KM, Bruden D, Parkinson A J, Hurlburt D, Getty M, et al. Changes in antibiotic-prescribing practices and carriage of penicillin-resistant Streptococcus pneumoniae: a controlled intervention trial in rural Alaska. Clin Infect Dis. 2002;34:1543-50.
(37.) Belongia EA, Sullivan BJ, Chyou PH, Madagame E, Reed KD, Schwartz B. A community intervention trial to promote judicious antibiotic use and reduce penicillin resistant Streptococcus pneumoniae carriage in children. Pediatrics. 2001;108:575-83.
Eva Melander, * ([dagger]) Hans-Bertil Hansson, ([dagger][double dagger]) Sigvard Molstad, ([double dagger]) Kristina Persson, ([dagger]) and Hakan Ringberg ([dagger])
* Department of Clinical Microbiology, Lund University Hospital, Lund, Sweden; ([dagger]) Regional Center for Communicable Disease Control, Skane County, Sweden; and ([double dagger]) Unit of Research and Development in Primary Health Care, Jonkoping County, Sweden
Dr. Melander is a physician in the Department of Medical Microbiology, Lund University Hospital, Lund, Sweden. Her main research interests include bacterial antimicrobial resistance and use of antimicrobial agents.
Address for correspondence: Eva Melander, Department of Clinical Microbiology and Immunology, Lund University Hospital, SE-221 85 Lund, Sweden; fax: +4646135936; email: email@example.com
|Printer friendly Cite/link Email Feedback|
|Publication:||Emerging Infectious Diseases|
|Date:||Jun 1, 2004|
|Previous Article:||Candida parapsilosis characterization in an outbreak setting.|
|Next Article:||Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States.|